Q3 2020 Sales Performance
40
40
Innovation
Our R&D pipeline
40 medicines and 18 vaccines
First time in human (Phase 1)
3858279* (CCL17 inhibitor) OA pain
3745417 (STING agonist) cancer
3186899* (CRK-12 inhibitor) visceral leishmaniasis
3511294* (LA anti-IL5 antagonist) asthma
3810109* (broadly neutralizing antibody) HIV
3537142* (NYES01 ImmTAC) cancer
3439171* (H-PGDS inhibitor) DMD
3368715* (Type 1 PRMT inhibitor) cancer
3174998* (OX40 agonist) cancer
2798745 (TRPV4) DME
6097608* (CD96) cancer
2982772 (RIP1-k) psoriasis
3882347* (Fim H antagonist) UUTI
3739937 (maturation inhibitor) HIV
3923868 (P14kẞ inhibitor) viral COPD exacerbations
3901961* (CD8 TCR) cancer
3845097* (TGFbR2 TCR) cancer
3494245* (proteasome inh) visceral leishmaniasis
C. difficile⭑
SAM (rabies model)
S. aureus*
COVID-19 (Clover Biopharmaceuticals)*+
COVID-19 (Medicago)**
COVID-19 (Sanofi)*12
Proof of concept (Phase 1b/2)
3640254 (maturation inhibitor) HIV
3228836* (HBV ASO) HBV
2330811 (OSM antagonist) systemic sclerosis
linerixibat (IBATI) cholestatic pruritus in PBC
3326595* (PRMT5 inhibitor) cancer
cobolimab* (TSR-022, TIM-3 antagonist) cancer
3036656* (leucyl t-RNA inhibitor) TB
2831781* (aLAG3 depleting) ulcerative colitis
4074386* (TSR-033, LAG3 antagonist) cancer
Menveo liquid
RSV paediatric
RSV maternal*
RSV older adults*2
Therapeutic HBV*2
Malaria (fractional dose)
Shigella*
Pivotal (Phase 2/3)
Benlysta³ Rituxan SLE**
cabotegravir** LA + rilpivirine* LA HIV
daprodustat (HIF-PHI) anemia
Nucala COPD / nasal polyps
Blenrep (BCMA ADC) multiple myeloma
Zejula (PARP inhibitor) ovarian cancer**
dostarlimab (PD-1 antagonist) dMMR/MSI-H EC
bintrafusp alfa* (TGFß trap/anti-PDL1) BTC**
otilimab (3196165, aGM-CSF inhibitor) RA**4
gepotidacin* (2140944) UUTI and GC
3359609* (ICOS receptor agonist) HNSCC**1
letetresgene-autoleucel* (3377794, NY-ESO-1 TCR) SS**
4182136* (Vir-7831) COVID-19
Shingrix immuno-compromised*
Bexsero infants (US)
MMR (US)
Rotarix liquid (US)
MenABCWY
Rx
Vx
gsk
Note: Only the most advanced indications are
shown for each asset
*In-license or other alliance relationship with third party
**Additional indications also under investigation
+ GSK is contributing pandemic adjuvant to COVID-19 vaccines
collaborations
1. ICOS HNSCC is a Phase 2/3 study with registrational
potential
2. In Phase 1/2 study
3. Benlysta for lupus nephritis in registration
4. Otilimab for COVID-19 therapy in Ph2
RA: rheumatoid arthritis; OA: osteoarthritis; DMD: duchenne
muscular dystrophy; PBC: primary biliary cholangitis;
TB: tuberculosis; SLE: systemic lupus erythematosus; BTC:
biliary tract cancer; EC: endometrial cancer; uUTI:
uncomplicated urinary tract infection; GC: gonorrhoea;
HNSCC: head and neck squamous cell carcinoma; dMMR:
deficient mismatch repair; DME: diabetic macular edemaView entire presentation